Accelerate Your
EV Programs
Eliminate the consistency barrier in extracellular vesicle development
Partnership Models
At-a-Glance
Choose Your Collaboration Path
-
Complete FT-01 technology access for specific therapeutic applications
-
Collaborative research programs in areas of mutual interest
-
Consultancy on your EV programme
The FT-01
Advantage
Why Partner With Us
Traditional EV development requires years of investment to establish consistent production capabilities, with no guarantee of success. FT-01 eliminates this barrier, offering partners immediate access to a validated, scalable platform.
-
Proven Scalability: 84% cost reduction demonstrated while maintaining product quality
GMP-Ready Processes: Regulatory documentation and quality systems established
Consistent Supply: Clonal cell line eliminates donor-dependent variability
Technical Expertise: Knowledge transfer and ongoing scientific support
Collaboration
In Action
Building Strategic Relationships
We're building connections with pharma and biotech partners who share our belief in the potential of EV therapeutics. Our growing network demonstrates high interest from commercial partners who recognise FT-01's transformative potential and broad therapeutic applicability.
-
New therapeutic areas using naïve EVs from FT-01
Precision-targeted delivery with tissue-specific EV engineering
Custom therapeutic payloads including nucleic acids, proteins, or small molecul
Strong alignment with key opinion leaders including Versus Arthritis, University of York, and world-class advisory board members supports the scientific credibility and commercial potential of our platform.
Our Proven Network
Supported by
Ready to Explore Collaboration
Whether you're interested in platform licensing, joint development, or manufacturing services, our team is available to discuss how FT-01 can accelerate your EV therapeutic goals.